Drug Trial Radar · NCT05150392
An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization
Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,193
Actual
Start
Jul 11, 2018
Primary completion
Aug 11, 2018
Study completion Aug 14, 2020
Sponsor
- Lead sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization
Conditions
- Varicella
Interventions
Investigational live attenuated varicella vaccineBiological
The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity index-seroconversion rate of antibodyTime frame: 1 year after primary immunization
- Immunogenicity index-seroconversion rate of antibodyTime frame: 2 years after primary immunization
- Immunogenicity index-seroconversion rate of antibodyTime frame: 3 years after primary immunization
- Immunogenicity index-Seroconversion rate of antibodyTime frame: 30 days after booster immunization
- Immunogenicity index-seropositivity rate of antibodyTime frame: 30 days after booster immunization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangfu County Center for Disease Control and Prevention
Kaifeng, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.